
Remicade100 mg/20
Unimed Unihealth MFG. Ltd.
Infliximab is a chimeric monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-alpha), administered by intravenous infusion for a range of chronic inflammatory and autoimmune conditions.
Infliximab is a chimeric monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-alpha), administered by intravenous infusion for a range of chronic inflammatory and autoimmune conditions. Its uses are classified below by strength of evidence.
| Indication | Induction Dose | Maintenance Dose |
|---|---|---|
| Rheumatoid arthritis (with methotrexate) | 3 mg/kg IV at weeks 0, 2, and 6 | 3 mg/kg every 8 weeks; may increase up to 10 mg/kg or shorten interval to every 4 weeks if response is inadequate |
| Crohn's disease / fistulizing Crohn's disease | 5 mg/kg IV at weeks 0, 2, and 6 | 5 mg/kg every 8 weeks |
| Ulcerative colitis | 5 mg/kg IV at weeks 0, 2, and 6 | 5 mg/kg every 8 weeks |
| Ankylosing spondylitis | 5 mg/kg IV at weeks 0, 2, and 6 | 5 mg/kg every 6 weeks |
| Psoriatic arthritis | 5 mg/kg IV at weeks 0, 2, and 6 | 5 mg/kg every 8 weeks |
| Plaque psoriasis | 5 mg/kg IV at weeks 0, 2, and 6 | 5 mg/kg every 8 weeks |
For pediatric Crohn's disease (age 6 years and older) and pediatric ulcerative colitis (age 6 years and older): 5 mg/kg IV at weeks 0, 2, and 6, then every 8 weeks thereafter, in combination with conventional therapy as appropriate. Safety and efficacy have not been established in children younger than 6 years for these indications, and Infliximab is not established for pediatric rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or plaque psoriasis (see Pediatric Uses).
Infliximab has not been formally studied in patients with renal or hepatic impairment, and no specific dose adjustment has been established; use with clinical judgment and monitoring. Infliximab should not be initiated in patients with active hepatic dysfunction, and therapy should be discontinued if new or worsening significant liver injury develops.
Infliximab must be administered only by a qualified healthcare professional as an intravenous infusion over at least 2 hours, using an in-line, low-protein-binding filter, in a setting equipped to manage infusion reactions and anaphylaxis. It must never be given as an intravenous push or bolus, and it is not for subcutaneous, intramuscular, or self-administered home use.
The most commonly reported side effects of Infliximab include:
Serious but less common effects include serious infections (including reactivation of tuberculosis and hepatitis B), malignancies including lymphoma, heart failure exacerbation, demyelinating neurologic disease, lupus-like syndrome, and severe hepatic reactions (see Precautions and Warnings). Patients should seek prompt medical attention for signs of infection, unusual bruising or bleeding, jaundice, chest pain, or severe allergic reaction while receiving Infliximab.
Infliximab is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.